TRIFLUOPERAZINE HCL
Clinical safety rating: safe
CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome.
Trifluoperazine is a typical antipsychotic of the phenothiazine class. It acts primarily as a dopamine D2 receptor antagonist, blocking postsynaptic dopamine receptors in the mesolimbic and mesocortical pathways. It also exhibits moderate anticholinergic, antiadrenergic, and antihistaminergic activity.
| Metabolism | Primarily hepatic via CYP1A2, with minor contributions from CYP2D6 and CYP3A4. Metabolites are excreted in urine and feces. |
| Excretion | Renal (as metabolites, less than 1% unchanged); fecal (biliary) elimination of metabolites accounts for a significant portion; total recovery in urine and feces accounts for >90% of a dose. |
| Half-life | 12-30 hours (terminal elimination half-life); clinical context: requires multiple daily dosing or extended-release formulations for steady-state maintenance. |
| Protein binding | 90-99% bound; primarily to albumin. |
| Volume of Distribution | 10-20 L/kg; large Vd indicates extensive tissue distribution and accumulation in peripheral compartments. |
| Bioavailability | Oral: 30-50% (due to first-pass metabolism); IM: 100%. |
| Onset of Action | Oral: 30-60 minutes; IM: 15-30 minutes; IV: 5-10 minutes. |
| Duration of Action | Oral: 6-12 hours; IM/IV: 4-6 hours; clinical note: effects on psychosis may require 2-4 weeks for full therapeutic response. |
| Molecular Weight | 480.4 |
2-10 mg orally twice daily; maximum 40 mg/day. For severe psychosis, 5-20 mg intramuscularly every 4-6 hours, maximum 30 mg/day.
| Dosage form | Injectable |
| Renal impairment | No specific adjustments in published guidelines; use with caution in severe renal impairment (GFR <30 mL/min) due to potential accumulation; monitor for extrapyramidal symptoms. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: avoid use or reduce dose by 75%. |
| Pediatric use | Children 6-12 years: 1-5 mg orally twice daily; maximum 20 mg/day. Not recommended under 6 years. |
| Geriatric use | Initiate at 1-2 mg orally twice daily; increase slowly; maximum 15 mg/day. Monitor for orthostatic hypotension, sedation, and extrapyramidal symptoms. |
| 1st trimester | Associated with increased risk of congenital malformations, particularly cardiovascular and neural tube defects; avoid use unless essential. |
| 2nd trimester | Use only if potential benefit justifies risk; may cause neonatal extrapyramidal symptoms and withdrawal reactions. |
| 3rd trimester | Avoid near term; risk of neonatal extrapyramidal symptoms, jaundice, and prolonged QT interval. |
Clinical note
CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome.
| FDA category | Animal |
| Placental transfer | Crosses placenta; detectable in fetal tissues and amniotic fluid. Animal studies show fetal transfer. |
| Breastfeeding |
■ FDA Black Box Warning
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Trifluoperazine is not approved for the treatment of dementia-related psychosis.
| Common Effects | Extrapyramidal symptoms |
| Serious Effects |
Hypersensitivity to trifluoperazine or phenothiazinesComatose statesCNS depressionBone marrow depressionKnown blood dyscrasias
| Precautions | Increased mortality in elderly patients with dementia-related psychosis, Tardive dyskinesia, Neuroleptic malignant syndrome (NMS), QT prolongation and arrhythmias, Leukopenia/neutropenia/agranulocytosis, Orthostatic hypotension, Seizure threshold lowering, Anticholinergic effects (e.g., confusion, urinary retention), Hyperprolactinemia, Photosensitivity |
| Food/Dietary |
Loading safety data…
| Excreted into breast milk; monitoring infant for sedation, irritability, and abnormal movements recommended. Consider alternative agents with lower risk. |
| Lactation Rating | L4 (Potentially Hazardous) |
| Teratogenic Risk | First trimester: Limited data; potential risk of congenital malformations (especially cardiovascular) based on animal studies and weak human association. Second/third trimester: Risk of extrapyramidal symptoms, withdrawal, and neonatal sedation after delivery. Antipsychotic use near term may cause neonatal toxicity. |
| Fetal Monitoring | Maternal: Baseline and periodic liver function tests, CBC, ECG if cardiac risk; monitor blood pressure, extrapyramidal symptoms, and mood changes. Fetal: Ultrasound for anatomy at 18-20 weeks; neonatal monitoring for extrapyramidal signs, respiratory depression, and feeding difficulties. |
| Fertility Effects | Trifluoperazine may elevate prolactin levels, potentially causing menstrual irregularities, galactorrhea, and reversible infertility due to anovulation. Men may experience reduced libido or erectile dysfunction. |
| Avoid excessive caffeine intake as it may worsen anxiety or agitation. Grapefruit juice may increase trifluoperazine levels; limit or avoid consumption. Alcohol can potentiate CNS depression and should be avoided. Maintain adequate hydration as constipation is common. |
| Clinical Pearls | Trifluoperazine is a high-potency typical antipsychotic; monitor for extrapyramidal symptoms (EPS) especially akathisia and acute dystonias, which may occur early in treatment. It can cause tardive dyskinesia with long-term use. QT prolongation is possible; obtain baseline ECG and monitor electrolytes. Avoid abrupt discontinuation to prevent withdrawal dyskinesia. Use with caution in elderly patients with dementia-related psychosis due to increased mortality risk. |
| Patient Advice | Take exactly as prescribed; do not stop abruptly without consulting your doctor. · You may experience dizziness or drowsiness; avoid driving or operating heavy machinery until you know how this medication affects you. · Contact your doctor immediately if you experience muscle stiffness, fever, confusion, or irregular heartbeat. · Avoid alcohol and other CNS depressants while taking this medication. · Report any unusual muscle movements, especially of the face, tongue, or jaw, as these may be signs of a serious side effect. |